Skip to content
IP + Technology Law
Home  »  News & Insights  »  Presentation

Knobbe Martens Webinar Series: Strategic Considerations in Patent Subject Matter Eligibility Under Section 101 – Revised Guidance Examples

November 19, 2020  | Mauricio Uribe and Dan Altman

EU Webinar_page_Banner_1_0.png

Partners Mauricio Uribe and Dan Altman presented a Webinar focused on strategic considerations for patent prosecution in the United States in view of the statutory requirements of Section 101.

View live presentation: Video Link

Knobbe Martens on Vimeo

View and download the full presentation below.
Knobbe Martens Webinar Series: Strategic Considerations in Patent Subject Matter Eligibility Under Section 101 – Revised Guidance Examples

Knobbe Martens Webinar Series: Strategic Considerations in Patent Subject Matter Eligibility Under Section 101 from Knobbe Martens – Intellectual Property Law
Knobbe Martens Webinar Series: Strategic Considerations in Patent Subject Matter Eligibility Under Section 101 – Revised Guidance Examples Headshot

Dan Altman
Partner
Orange County
dan.altman@knobbe.com
949-760-0404

Related Links

Practice Areas

News & Insights

Blog - Biotechnology
May 2026
Federal Circuit Confirms Patent Eligibility of Gene Therapy Patent in Regenexbio Inc. v. Sarepta Therapeutics
Key Takeaway: Genetically engineered cultured host cells containing recombinant nucleic acids useful for gene therapy are patent-eligible for being markedly different from anything occurring in nature. In REGENXBIO Inc. v....
Publications
Apr 2026
Alistair McIntyre and Tom Cowan Explore Latest Section 101 Patent Eligibility Developments in Inventors Digest Article
In their recent Inventors Digest article, Knobbe Martens lawyers Alistair McIntyre and Tom Cowan examine key developments in Section 101 patent eligibility, and offer practical guidance for inventors navigating complex...
Publications
May 2026
USPTO Director Signals Continued Pro-Patent Discretionary Denial Policy at the Patent Trial and Appeal Board
Key Takeaway: In a precedential decision in Magnolia Medical Technologies, Inc. v. Kurin, Inc., USPTO Director Squires denied IPR institution and reinforced the policy framework for discretionary denial at the...